Biotechnology

  1. Biotechnology

New patent expiration for Ferrer Internacional drug XEPI – DrugPatentWatch

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for XEPI Xepi is a drug marketed by Ferrer Internacional and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. This drug has forty-four patent family members in twenty-five countries. The generic ingredient in XEPI […]
Written by
German Research Foundation renews funding for Research Training Group
  1. Biotechnology

German Research Foundation renews funding for Research Training Group

Over the past four and a half years, Mainz University has made significant advances in unravelling the role of gene regulation in adaptation and evolution by combining evolutionary and molecular biology within its doctoral training program. As a result, the German Research Foundation (DFG) has agreed to extend funding for the Research Training Group 2526 […]
Written by
Labiotech.eu
  1. Biotechnology

Eight biotech companies tackling infectious diseases head-on

Infectious diseases are diseases that are caused by pathogens that enter the body, hijack the body’s immune system and multiply, causing an infection. Five of the deadliest infectious diseases are measles, tuberculosis, malaria, diarrhoeal disease and influenza, according to the World Economic Forum. While Our World in Data statistics suggest that there has been almost […]
Written by
Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
  1. Biotechnology

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics

Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond. Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment of adult and pediatric patients two years of age and older with relapsed or […]
Written by
  1. Biotechnology

New patent for Beigene drug BRUKINSA – DrugPatentWatch

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/ Annual Drug Patent Expirations for BRUKINSA Brukinsa is a drug marketed by Beigene and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. This drug has forty-nine patent family members in twenty-eight countries. The generic ingredient in BRUKINSA is […]
Written by
Some benefits of exercise stem from the immune system
  1. Biotechnology

Some benefits of exercise stem from the immune system

The connection between exercise and inflammation has captivated the imagination of researchers ever since an early 20th-century study showed a spike of white cells in the blood of Boston marathon runners following the race. The connection between exercise and inflammation has captivated the imagination of researchers ever since an early 20th-century study showed a spike of white cells in […]
Written by
Labiotech.eu
  1. Biotechnology

How French pharma giant Sanofi is betting big on AI

The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching the attention of big pharma […]
Written by
Cellectis and AstraZeneca in US$2.2bn deal
  1. Biotechnology

Cellectis and AstraZeneca in US$2.2bn deal

AstraZeneca plc has paid French cancer cell therapy developer Cellectis SA US$25m upfront and US$220m in equity in an US$2.2bn R&D deal for up to ten cell and gene therapies. Under the co-development agreement, that includes a US$80m equity investment and an option for a further equity investment of US$140m by AstraZeneca plc into Cellectis […]
Written by

Good Reads

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

LOS ALTOS, Calif., June 30, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease…
Written by

Robotic Probe Rapidly Assesses Essential Properties of Novel Materials

In the quest to conquer the limitations of semiconductor materials and their application in solar technologies, a pioneering research team at the Massachusetts Institute of Technology (MIT) has developed an innovative autonomous robotic system. This advancement comes at a crucial time when the demand for efficient energy sources continues to rise. Researchers face significant bottlenecks […]
Written by

Worlwide

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

LOS ALTOS, Calif., June 30, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease…
Written by

Robotic Probe Rapidly Assesses Essential Properties of Novel Materials

In the quest to conquer the limitations of semiconductor materials and their application in solar technologies, a pioneering research team at the Massachusetts Institute of Technology (MIT) has developed an innovative autonomous robotic system. This advancement comes at a crucial time when the demand for efficient energy sources continues to rise. Researchers face significant bottlenecks […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.